Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed and Gemcitabine in KRAS-mutant mCRC
NCT01109615Phase 2Terminated
- Sponsor
- Vejle Hospital
- Start
- Apr 2010
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and gemcitabine in metastatic colorectal cancer (mCRC), sponsored by Vejle Hospital. Primary endpoint: Response Rate at 12 months. Started Apr 2010; status: terminated.
02
Drugs
pemetrexedgemcitabine
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01109615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01109615.